Department of Pediatrics, Section of Nephrology, Yale University School of Medicine, New Haven, Connecticut
Program of Applied Translational Research, Yale University School of Medicine, New Haven, Connecticut.
J Am Soc Nephrol. 2020 May;31(5):1067-1077. doi: 10.1681/ASN.2019070723. Epub 2020 Mar 31.
After accounting for known risk factors for CKD progression in children, clinical outcomes among children with CKD still vary substantially. Biomarkers of tubular injury (such as KIM-1), repair (such as YKL-40), or inflammation (such as MCP-1, suPAR, TNF receptor-1 [TNFR-1], and TNFR-2) may identify children with CKD at risk for GFR decline.
We investigated whether plasma KIM-1, YKL-40, MCP-1, suPAR, TNFR-1, and TNFR-2 are associated with GFR decline in children with CKD and in subgroups defined by glomerular versus nonglomerular cause of CKD. We studied participants of the prospective CKiD Cohort Study which enrolled children with an eGFR of 30-90 ml/min per 1.73 m and then assessed eGFR annually. Biomarkers were measured in plasma collected 5 months after study enrollment. The primary endpoint was CKD progression, defined as a composite of a 50% decline in eGFR or incident ESKD.
Of the 651 children evaluated (median age 11 years; median baseline eGFR of 53 ml/min per 1.73 m), 195 (30%) had a glomerular cause of CKD. Over a median follow-up of 5.7 years, 223 children (34%) experienced CKD progression to the composite endpoint. After multivariable adjustment, children with a plasma KIM-1, TNFR-1, or TNFR-2 concentration in the highest quartile were at significantly higher risk of CKD progression compared with children with a concentration for the respective biomarker in the lowest quartile (a 4-fold higher risk for KIM-1 and TNFR-1 and a 2-fold higher risk for TNFR-2). Plasma MCP-1, suPAR, and YKL-40 were not independently associated with progression. When stratified by glomerular versus nonglomerular etiology of CKD, effect estimates did not differ significantly.
Higher plasma KIM-1, TNFR-1, and TNFR-2 are independently associated with CKD progression in children.
在考虑了儿童慢性肾脏病(CKD)进展的已知危险因素后,CKD 患儿的临床结局仍存在很大差异。肾小管损伤(如 KIM-1)、修复(如 YKL-40)或炎症(如 MCP-1、suPAR、TNF 受体-1[TNFR-1]和 TNFR-2)的生物标志物可能有助于识别肾小球性和非肾小球性 CKD 患儿中肾小球滤过率(GFR)下降的风险。
我们研究了血浆 KIM-1、YKL-40、MCP-1、suPAR、TNFR-1 和 TNFR-2 是否与 CKD 患儿及肾小球性和非肾小球性 CKD 亚组的 GFR 下降相关。我们研究了前瞻性 CKiD 队列研究的参与者,该研究纳入了 eGFR 为 30-90 ml/min/1.73 m2 的患儿,并每年评估 eGFR。在研究入组后 5 个月采集血浆,测量生物标志物。主要终点是 CKD 进展,定义为 eGFR 下降 50%或发生终末期肾病(ESKD)。
在 651 名评估的患儿中(中位年龄 11 岁;中位基线 eGFR 为 53 ml/min/1.73 m2),195 名(30%)患儿的 CKD 病因是肾小球性。中位随访 5.7 年后,223 名(34%)患儿发生了 CKD 进展至复合终点。经多变量调整后,与生物标志物浓度处于最低四分位数的患儿相比,KIM-1、TNFR-1 或 TNFR-2 浓度处于最高四分位数的患儿发生 CKD 进展的风险显著更高(KIM-1 和 TNFR-1 的风险增加 4 倍,TNFR-2 的风险增加 2 倍)。血浆 MCP-1、suPAR 和 YKL-40 与进展无独立相关性。按肾小球性和非肾小球性 CKD 病因分层时,效应估计值无显著差异。
较高的血浆 KIM-1、TNFR-1 和 TNFR-2 与儿童 CKD 进展独立相关。